Endocrine Pharmacology Practice Questions

Q: A 50-year-old male with type 2 diabetes is prescribed a new medication to manage his condition. Which drug reduces postprandial hyperglycemia without increasing insulin levels?

Voglibose. ***Voglibose*** - **Voglibose** is an alpha-glucosidase inhibitor that works by delaying the digestion and absorption of carbohydrates in the small intestine. - This mechanism specifically reduces the postprandial rise in blood glucose without directly affecting insulin secretion or sensitivity. *Metformin* - **Metformin** primarily reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. - It does not specifically target postprandial hyperglycemia by delaying carbohydrate absorption to the extent that alpha-glucosidase inhibitors do, nor does it increase insulin levels. *Glibenclamide* - **Glibenclamide** is a sulfonylurea that stimulates insulin release from pancreatic beta cells. - This mechanism directly increases insulin levels, which is contrary to the question's premise. *Pioglitazone* - **Pioglitazone** is a thiazolidinedione (TZD) that improves insulin sensitivity in adipose tissue, muscle, and liver. - While it helps manage blood glucose, its primary action is not to reduce postprandial hyperglycemia without altering insulin levels; rather, it improves the body's response to existing insulin.

Q: A patient is diagnosed with hyperthyroidism and prescribed a drug that inhibits thyroid hormone synthesis. Which drug is appropriate in this case?

Methimazole. ***Methimazole*** - **Methimazole** is an **antithyroid drug** that inhibits the synthesis of thyroid hormones by interfering with the organification of iodine and coupling of iodotyrosines. - It is a first-line treatment for **hyperthyroidism** and is effective in reducing excessive thyroid hormone production. *Levothyroxine* - **Levothyroxine** is a **synthetic thyroid hormone (T4)** used to treat **hypothyroidism**, not hyperthyroidism. - Administering levothyroxine to a patient with hyperthyroidism would worsen their condition by increasing thyroid hormone levels. *Propranolol* - **Propranolol** is a **beta-blocker** used to manage the symptomatic effects of hyperthyroidism, such as **tachycardia**, **tremors**, and **anxiety**. - It does not inhibit thyroid hormone synthesis but rather blocks the effects of excess thyroid hormones on target organs. *Amiodarone* - **Amiodarone** is an antiarrhythmic drug that contains iodine, and it can cause **thyroid dysfunction**, including both **hypothyroidism** and **hyperthyroidism**, due to its iodine content and direct toxic effects on the thyroid. - It does not inhibit thyroid hormone synthesis and is not used as a primary treatment for hyperthyroidism.

Q: What is the initial pharmacological treatment for a postmenopausal woman diagnosed with osteoporosis?

Bisphosphonates. ***Bisphosphonates*** - **Bisphosphonates** are considered the **first-line pharmacological treatment** for most patients with osteoporosis due to their proven efficacy in reducing fracture risk. - They work by **inhibiting osteoclast activity**, thereby decreasing bone resorption and increasing bone mineral density. *Calcium and vitamin D supplements* - While essential for **bone health** and often prescribed alongside other treatments, **calcium and vitamin D supplements** alone are generally not sufficient as the **initial pharmacological treatment** for established osteoporosis. - They are considered foundational support but do not have the same **fracture risk reduction** efficacy as bisphosphonates for patients with diagnosed osteoporosis. *Calcitonin* - **Calcitonin** is a therapeutic option for osteoporosis, but it is typically reserved for patients who cannot tolerate other treatments or for short-term pain relief from acute vertebral fractures. - Its efficacy in reducing non-vertebral fractures is less robust compared to bisphosphonates, making it a **second-line or alternative agent**. *Selective estrogen receptor modulators (SERMs)* - **SERMs** (e.g., raloxifene) are used in osteoporosis treatment, particularly when there is a need to also address **breast cancer risk**. - While effective in preventing vertebral fractures, they are generally **not the first-line choice** for overall fracture prevention, and bisphosphonates are preferred for initial broad-spectrum management of osteoporosis.

Q: Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

Metformin. ***Metformin (Correct)*** - **Metformin** is a biguanide that primarily lowers blood glucose by activating **AMP-activated protein kinase (AMPK)**. - This activation improves **insulin sensitivity**, reduces hepatic glucose production, and decreases intestinal glucose absorption. - Metformin is the first-line oral agent for type 2 diabetes and works through AMPK-dependent mechanisms. *Glibenclamide (Incorrect)* - **Glibenclamide** is a sulfonylurea that stimulates insulin secretion from beta cells by blocking **ATP-sensitive potassium channels**. - It does not primarily improve **insulin sensitivity** or activate AMPK. - It works by increasing insulin release, not improving insulin action. *Pioglitazone (Incorrect)* - **Pioglitazone** is a thiazolidinedione (TZD) that improves **insulin sensitivity** by activating **peroxisome proliferator-activated receptor-gamma (PPAR-γ)** in adipose tissue. - While it enhances insulin sensitivity, its mechanism of action is distinct from AMPK activation. - This is an important distractor as it also improves insulin sensitivity but through a different pathway. *Acarbose (Incorrect)* - **Acarbose** is an alpha-glucosidase inhibitor that reduces post-prandial glucose levels by delaying carbohydrate digestion and absorption in the intestine. - It does not directly improve **insulin sensitivity** or act via the AMPK pathway. - It works by slowing glucose absorption, not by improving cellular insulin response.

Q: A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

They inhibit ovulation. ***They inhibit ovulation*** - Oral contraceptive pills (OCPs) primarily act by suppressing the **hypothalamic-pituitary-ovarian axis**, preventing the surge of **luteinizing hormone (LH)** required for ovulation. - The **estrogen and progestin** components in OCPs provide negative feedback, leading to inconsistent follicular development and the absence of a dominant follicle. *They increase uterine contractility* - OCPs generally **decrease uterine contractility** to prevent implantation, rather than increase it in a way that would expel a pregnancy. - Increased uterine contractility could potentially interfere with implantation, but this is not the primary mechanism of action of OCPs for preventing conception. *They alter the pH of the vagina* - OCPs do **not significantly alter the vaginal pH** as a primary mechanism for preventing pregnancy. - Changes in vaginal pH are more commonly associated with methods like spermicides or natural physiological variations, not hormonal contraception. *They promote the thickening of cervical mucus* - While OCPs do cause the **thickening of cervical mucus**, making it difficult for sperm to penetrate and reach the egg, this is a **secondary mechanism**. - The **primary and most effective mechanism** is the inhibition of ovulation.

Q: What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

Inhibit osteoclast activity. ***Inhibit osteoclast activity*** - Bisphosphonates are analogs of **pyrophosphate** that bind to **hydroxyapatite crystals** in the bone matrix. - Once internalized by osteoclasts during bone resorption, they disrupt the **mevalonate pathway**, leading to osteoclast apoptosis and reduced bone breakdown. *Enhance calcium absorption* - This is primarily the role of **Vitamin D**, which promotes calcium uptake from the gut. - Bisphosphonates do not directly affect **intestinal calcium absorption**. *Stimulate osteoblast activity* - Drugs like **teriparatide** (a parathyroid hormone analog) are known to stimulate osteoblast function and new bone formation. - Bisphosphonates primarily act to reduce bone resorption, not directly stimulate **bone formation**. *Increase parathyroid hormone levels* - **Parathyroid hormone (PTH)** plays a key role in calcium homeostasis, and chronically elevated PTH can lead to bone resorption. - Bisphosphonates do not increase PTH levels; instead, they work independently to strengthen bone.

Q: Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

Pioglitazone. ***Pioglitazone*** - **Pioglitazone** is a **thiazolidinedione (TZD)** that exerts its effects by activating **PPAR-γ** receptors. - Activation of **PPAR-γ** leads to increased **insulin sensitivity** in peripheral tissues and the liver, reducing insulin resistance. *Glibenclamide* - **Glibenclamide** is a **sulfonylurea** that works by stimulating **insulin secretion** from pancreatic **beta cells**. - It binds to the **sulfonylurea receptor 1 (SUR1)** on the **ATP-sensitive potassium channel**, causing depolarization and insulin release, not increased insulin sensitivity. *Metformin* - **Metformin** is a **biguanide** that primarily reduces **hepatic glucose production** and slightly increases peripheral glucose uptake. - Its main mechanism involves activation of **AMP-activated protein kinase (AMPK)**, not **PPAR-γ**. *Acarbose* - **Acarbose** is an **alpha-glucosidase inhibitor** that delays the digestion and absorption of carbohydrates in the gastrointestinal tract. - It reduces postprandial glucose excursions by interfering with carbohydrate breakdown, rather than affecting insulin sensitivity directly.

Q: What is the first-line drug for osteoporosis in postmenopausal women?

Bisphosphonates. ***Bisphosphonates*** - **Bisphosphonates** are the **first-line treatment** for osteoporosis due to their proven efficacy in reducing fracture risk by inhibiting osteoclast activity. - They bind to bone mineral and are internalized by osteoclasts, leading to their **apoptosis** and decreased bone resorption. *OCP* - **Oral contraceptives (OCP)** are not used for treating established osteoporosis; they may have a minor protective effect against bone loss in premenopausal women but are not a primary therapeutic agent postmenopause. - OCPs primarily contain **estrogen and/or progestin** and are used for contraception and managing menstrual irregularities. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, especially if there's a concern for breast cancer, but it is typically a second-line option. - Although it mimics estrogen's beneficial effects on bone, it does not have the same overall fracture reduction efficacy as bisphosphonates and can increase the risk of **venous thromboembolism**. *Strontium* - **Strontium ranelate** is an anti-osteoporotic agent that both inhibits bone resorption and promotes bone formation. - Its use has been limited due to concerns about serious side effects, including an increased risk of **cardiovascular events** and **venous thromboembolism**, making it a less favored option compared to bisphosphonates.

Q: Norgestimate in OC pills has the following advantage?

Reduces acne and hirsutism. ***reduces acne and hirsutism*** - **Norgestimate** is a third-generation progestin known for its **low androgenic activity**, which helps to counteract the androgenic effects that can contribute to acne and hirsutism when combined with estrogen. - By minimizing androgenic side effects, norgestimate-containing oral contraceptive pills (OCPs) can improve skin conditions such as **acne** and unwanted hair growth (**hirsutism**), making them a preferred choice for patients with these concerns. *May reduce the risk of venous thrombosis* - While some progestins are associated with varying risks of venous thrombosis, norgestimate does not inherently **reduce** this risk compared to other progestins; in fact, all combined OCPs carry some increased risk. - The risk of **venous thromboembolism (VTE)** is primarily influenced by the estrogen component and the specific type and dose of progestin, but norgestimate is not specifically noted for reducing this risk. *Is generally more affordable than standard OC pills* - The cost of OCPs can vary widely based on brand, generic availability, and insurance coverage; norgestimate-containing pills are not inherently more affordable than other standard OCPs. - In some cases, newer formulations or brand-name versions of norgestimate-containing pills may even be **more expensive** than older, generic alternatives. *May have cardiovascular benefits* - Combined oral contraceptives, including those with norgestimate, generally do not offer **cardiovascular benefits** and may even increase the risk of cardiovascular events, particularly in women with pre-existing risk factors. - Long-term use of OCPs, especially in smokers or those with hypertension, can elevate the risk of conditions like **myocardial infarction** and **stroke**, rather than providing benefits.

Q: What are the active ingredients in the NuvaRing contraceptive?

Ethinyl estradiol + Etonogestrel. ***Ethinyl estradiol + Etonogestrel*** - The NuvaRing (vaginal ring) contains a combination of **ethinyl estradiol** (an estrogen) and **etonogestrel** (a progestin). - These hormones work together to prevent ovulation, thicken cervical mucus, and thin the uterine lining, thereby preventing pregnancy. *Ethinyl estradiol + Drospirenone* - This combination of hormones is found in some **oral contraceptive pills** (e.g., Yaz, Yasmin), not the NuvaRing. - Drospirenone is a **progestin** with anti-mineralocorticoid activity. *Levonorgestrel* - **Levonorgestrel** is a progestin used alone in various contraceptive methods, such as **emergency contraception** (e.g., Plan B), some intrauterine devices (IUDs), and progestin-only pills. - It is not the sole active ingredient, nor is it combined with ethinyl estradiol, in the NuvaRing. *Levonorgestrel + Ethinyl estradiol* - This combination is found in many **combination oral contraceptive pills** and some contraceptive patches. - While it contains both an estrogen and a progestin, the specific progestin in NuvaRing is etonogestrel, not levonorgestrel.

Question 1

A 50-year-old male with type 2 diabetes is prescribed a new medication to manage his condition. Which drug reduces postprandial hyperglycemia without increasing insulin levels?

Accepted Answer

Voglibose

Answer

Metformin

Answer

Glibenclamide

Answer

Pioglitazone

Question 2

A patient is diagnosed with hyperthyroidism and prescribed a drug that inhibits thyroid hormone synthesis. Which drug is appropriate in this case?

Accepted Answer

Methimazole

Answer

Levothyroxine

Answer

Propranolol

Answer

Amiodarone

Question 3

What is the initial pharmacological treatment for a postmenopausal woman diagnosed with osteoporosis?

Accepted Answer

Bisphosphonates

Answer

Calcium and vitamin D supplements

Answer

Calcitonin

Answer

Selective estrogen receptor modulators (SERMs)

Question 4

Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

Accepted Answer

Metformin

Answer

Glibenclamide

Answer

Pioglitazone

Answer

Acarbose

Question 5

A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

Accepted Answer

They inhibit ovulation

Answer

They increase uterine contractility

Answer

They alter the pH of the vagina

Answer

They promote the thickening of cervical mucus

Question 6

What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

Accepted Answer

Inhibit osteoclast activity

Answer

Enhance calcium absorption

Answer

Stimulate osteoblast activity

Answer

Increase parathyroid hormone levels

Question 7

Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

Accepted Answer

Pioglitazone

Answer

Glibenclamide

Answer

Metformin

Answer

Acarbose

Question 8

What is the first-line drug for osteoporosis in postmenopausal women?

Accepted Answer

Bisphosphonates

Answer

OCP

Answer

Raloxifene

Answer

Strontium

Question 9

Norgestimate in OC pills has the following advantage?

Accepted Answer

Reduces acne and hirsutism

Answer

May reduce the risk of venous thrombosis

Answer

Is generally more affordable than standard OC pills

Answer

May have cardiovascular benefits

Question 10

What are the active ingredients in the NuvaRing contraceptive?

Accepted Answer

Ethinyl estradiol + Etonogestrel

Answer

Ethinyl estradiol + Drospirenone

Answer

Levonorgestrel

Answer

Levonorgestrel + Ethinyl estradiol

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?